Literature DB >> 16685578

Prevalence of peripheral arterial disease - results of the Heinz Nixdorf recall study.

Knut Kröger1, Andreas Stang, Jana Kondratieva, Susanne Moebus, Eva Beck, Axel Schmermund, Stefan Möhlenkamp, Nico Dragano, Johannes Siegrist, Karl-Heinz Jöckel, Raimund Erbel.   

Abstract

BACKGROUND: This report presents population-based estimates of the prevalence of peripheral arterial disease (PAD), chronic critical limb ischemia (CLI), and Moenckeberg's medial calcinosis (MC) in Germany. PATIENTS AND METHODS: From the year 2000 to 2003, a total of 4,814 subjects aged 45-75 years were included in the study. In 30 of the subjects (0.6%), determination of the ankle brachial index (ABI) was not possible, leaving 4,735 subjects (99.4%) in the data set. PAD was considered present in all subjects with an ABI < 0.9 in one leg, and/or a history of prior treatment for PAD. CLI was considered present if the highest ankle artery pressure measured < 70 mmHg. Prevalence of MC was calculated for ABI cut-off values of 1.3 and 1.5.
FINDINGS: The overall prevalence of PAD according to the ABI criteria was 6.4% among men and 5.1% among women. After accounting for history of PAD, the prevalence increased to 8.2% among men and 5.5% among women. Taking the ABI criteria and medical history into account, males had a higher prevalence of PAD, with large increases in males aged 65-69 and 70-75 years. Chronic CLI was rare in the investigated population, and was found in only five older subjects (0.1%). With the criterion of ABI > 1.3, about 13.3% of males and 6.9% of females had MC. In contrast to PAD, the prevalence of MC did not increase with age. With the criterion of ABI > 1.5, MC was present in only 1.1% and 0.5% of men and women, respectively, but only 30 (0.6%) subjects had incompressible ankle arteries with a cuff pressure > 260 mmHg.
CONCLUSION: Prevalences of PAD based only on ABI generally underestimate the true prevalence of PAD in population-based studies. CLI predominantly affects older subjects. In addition, cut-off values for MC must be newly determined.

Entities:  

Mesh:

Year:  2006        PMID: 16685578     DOI: 10.1007/s10654-006-0015-9

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  37 in total

1.  The role of comorbidity in the assessment of intermittent claudication in older adults.

Authors:  A B Newman; B L Naydeck; K Sutton-Tyrrell; J F Polak; L H Kuller
Journal:  J Clin Epidemiol       Date:  2001-03       Impact factor: 6.437

2.  The prevalence of peripheral arterial disease and medial arterial calcification in patients with chronic renal failure: requirements for diagnostics.

Authors:  Yrjö Leskinen; Juha P Salenius; Terho Lehtimäki; Heini Huhtala; Heikki Saha
Journal:  Am J Kidney Dis       Date:  2002-09       Impact factor: 8.860

3.  [The problem of response in epidemiological studies in Germany (part I)].

Authors:  U Latza; A Stang; M Bergmann; A Kroke; S Sauer; R Holle; P Kamtsiuris; C Terschüren; W Hoffmann
Journal:  Gesundheitswesen       Date:  2004-05

4.  Asymptomatic peripheral arterial occlusive disease predicted cardiovascular morbidity and mortality in a 7-year follow-up study.

Authors:  J D Hooi; A D M Kester; H E J H Stoffers; P E L M Rinkens; J A Knottnerus; J W van Ree
Journal:  J Clin Epidemiol       Date:  2004-03       Impact factor: 6.437

5.  Peripheral arterial disease in the elderly: The Rotterdam Study.

Authors:  W T Meijer; A W Hoes; D Rutgers; M L Bots; A Hofman; D E Grobbee
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-02       Impact factor: 8.311

6.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

7.  [Moenckeberg media sclerosis: clinical aspects in diabetic patients].

Authors:  M Hirschl; M Francesconi; M M Hirschl
Journal:  Vasa       Date:  1991       Impact factor: 1.961

8.  High prevalence of peripheral arterial disease in persons with renal insufficiency: results from the National Health and Nutrition Examination Survey 1999-2000.

Authors:  Ann M O'Hare; David V Glidden; Caroline S Fox; Chi-Yuan Hsu
Journal:  Circulation       Date:  2004-01-19       Impact factor: 29.690

9.  Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000.

Authors:  Elizabeth Selvin; Thomas P Erlinger
Journal:  Circulation       Date:  2004-07-19       Impact factor: 29.690

10.  Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms.

Authors:  Mary McGrae McDermott; Kiang Liu; Philip Greenland; Jack M Guralnik; Michael H Criqui; Cheeling Chan; William H Pearce; Joseph R Schneider; Luigi Ferrucci; Lillian Celic; Lloyd M Taylor; Ed Vonesh; Gary J Martin; Elizabeth Clark
Journal:  JAMA       Date:  2004-07-28       Impact factor: 56.272

View more
  27 in total

1.  Unusual presentation of Mönckeberg's sclerosis in the thyroid vessels of three female patients.

Authors:  Christina Dastamani; Evi Kairi; Vassilis Arapoglou; Emmanouela Vouza; Eleni Karvouni; Agatha Kondi-Pafiti
Journal:  Int J Angiol       Date:  2010

2.  Radiographic manifestations of Mönckeberg arteriosclerosis in the head and neck region.

Authors:  Mehrnaz Tahmasbi-Arashlow; Sevin Barghan; Deeba Kashtwari; Madhu K Nair
Journal:  Imaging Sci Dent       Date:  2016-03-24

3.  [Update peripheral arterial occlusive disease].

Authors:  E Blessing
Journal:  Herz       Date:  2015-11       Impact factor: 1.443

4.  In vitro stent lumen visualisation of various common and newly developed femoral artery stents using MR angiography at 1.5 and 3 tesla.

Authors:  R Syha; D Ketelsen; M Kaempf; S Mangold; S Sixt; T Zeller; F Springer; F Schick; C D Claussen; K Brechtel
Journal:  Eur Radiol       Date:  2012-08-17       Impact factor: 5.315

5.  Randomized comparison of effects of suture-based and collagen-based vascular closure devices on post-procedural leg perfusion.

Authors:  H I M Kälsch; H Eggebrecht; S Mayringer; T Konorza; B Sievers; S Sack; R Erbel; K Kroeger
Journal:  Clin Res Cardiol       Date:  2007-09-18       Impact factor: 5.460

6.  Arterial calcifications and increased expression of vitamin D receptor targets in mice lacking TIF1alpha.

Authors:  Mihaela Ignat; Marius Teletin; Johan Tisserand; Konstantin Khetchoumian; Christine Dennefeld; Pierre Chambon; Régine Losson; Manuel Mark
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

7.  Prevalence of Calcification in Human Femoropopliteal Arteries and its Association with Demographics, Risk Factors, and Arterial Stiffness.

Authors:  Alexey Kamenskiy; William Poulson; Sylvie Sim; Austin Reilly; Jiangtao Luo; Jason MacTaggart
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-01-25       Impact factor: 8.311

8.  Midday naps and the risk of coronary artery disease: results of the Heinz Nixdorf Recall Study.

Authors:  Andreas Stang; Nico Dragano; Susanne Moebus; Stefan Möhlenkamp; Axel Schmermund; Hagen Kälsch; Raimund Erbel; Karl-Heinz Jöckel
Journal:  Sleep       Date:  2012-12-01       Impact factor: 5.849

9.  Cardiovascular risk factors and signs of subclinical atherosclerosis in the Heinz Nixdorf Recall Study.

Authors:  Raimund Erbel; Stefan Möhlenkamp; Karl-Heinz Jöckel; Nils Lehmann; Susanne Moebus; Barbara Hoffmann; Axel Schmermund; Andreas Stang; Johannes Siegrist; Nico Dragano; Dietrich Grönemeyer; Rainer Seibel; Klaus Mann; Martina Bröcker-Preuss; Knut Kröger; Lothar Volbracht
Journal:  Dtsch Arztebl Int       Date:  2008-01-07       Impact factor: 5.594

10.  Daily siesta, cardiovascular risk factors, and measures of subclinical atherosclerosis: results of the Heinz Nixdorf Recall Study.

Authors:  Andreas Stang; Nico Dragano; Charles Poole; Susanne Moebus; Stefan Möhlenkamp; Axel Schmermund; Johannes Siegrist; Raimund Erbel; Karl-Heinz Jöckel
Journal:  Sleep       Date:  2007-09       Impact factor: 5.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.